Trials / Sponsors / Elpiscience Biopharma, Ltd.
Elpiscience Biopharma, Ltd.
Industry · 6 registered clinical trials.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Withdrawn | A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid T Advanced Solid Tumor | Phase 1 | 2023-04-21 |
| Completed | A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors Advanced Solid Tumor | Phase 1 | 2021-12-23 |
| Completed | A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors Solid Tumor, Neoplasms, Malignant Tumor | Phase 1 | 2021-10-15 |
| Withdrawn | A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors Thoracic Tumors, Non-small Cell Lung Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | 2021-07-01 |
| Completed | A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors Solid Tumors, Neoplasms, Malignant Tumor | Phase 1 | 2021-04-01 |
| Terminated | A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Solid Tumors Solid Tumors, Neoplasms, Malignant Tumor | Phase 1 | 2019-06-28 |